Daiichi Sankyo (OTCPK:DSKYF)(OTCPK:DSNKY) reports that more than 97% of eligible claimants have opted into the product liability settlement program related to olmesartan products ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The People's Bank of China has announced that it would leave key interest rates unchanged. Following a meeting of the Monetary Policy Committee, a decision was made by the central bank to maintain its ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

(Alliance News) - AstraZeneca PLC on Monday said Datroway has been approved in the US for patients with a type of breast cancer. The Cambridge-based pharmaceuticals firm explained the final approval ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, ...

Even before the FDA's recent approval of Dato-DXd in breast cancer, analysts predicted sales of the antibody-drug conjugate ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...